BSX - Boston Scientific Corporation
| Previous Close | 28.840 |
| Open | 29.040 |
| Bid | 28.910 x 600 |
| Ask | 28.920 x 700 |
| Day's Range | 28.745 - 29.040 |
| 52 Week Range | 24.540 - 29.930 |
| Volume | 1,287,225 |
| Avg. Volume | 7,478,156 |
| Market Cap | 39.854B |
| Beta | 0.99 |
| PE Ratio (TTM) | 380.13 |
| EPS (TTM) | 0.076 |
| Earnings Date | Apr 25, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.84 |
- Investor's Business Daily•4 days ago
Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.
- ACCESSWIRE•5 days ago
Wired News – Boston Scientific Acquires California-Based nVision Medical
Stock Monitor: CHF Solutions Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on Boston Scientific Corp. (NYSE: BSX ). If ...
- American City Business Journals•6 days ago
Boston Scientific buys Harker School grad's med-tech business for $275M
San Bruno-based nVision makes a microcatheter device used to screen for ovarian cancer and was founded by a 32-year-old female CEO who was honored last year as a distinguished alumnus of the Harker School in San Jose. She had raised only $17 million in venture funding before the sale.
- Zacks•6 days ago
Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?
Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.
- American City Business Journals•6 days ago
Boston Scientific buys nVision Medical for $275 million
California-based nVision makes a microcatheter device used to screen for ovarian cancer.
- PR Newswire•7 days ago
Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences
The '550 patent was the only Edwards patent that Boston Scientific was found to infringe in the March 2017 German District Court litigation between the companies and is also the sole basis of Edwards' infringement action against Boston Scientific in Ireland. While Edwards has the right to appeal the EPO's decision, Boston Scientific believes the Edwards patent revocation will have a positive impact on both suits.
- Forbes•7 days ago
A 32-Year-Old's Startup, Inspired By A Health Scare, Sells For $275 Million
Surbhi Sarna decided she wanted to start a woman's health company after she suffered from an ovarian cyst so painful she passed out at age 15. Now she is 32, and her company is being bought by Boston Scientific.
- PR Newswire•7 days ago
Boston Scientific Announces Acquisition Of nVision Medical Corporation
MARLBOROUGH, Mass., April 16, 2018 /PRNewswire/ -- Boston Scientific (BSX) today announced that it has acquired nVision Medical Corporation, a privately-held company focused on women's health. Ovarian cancer is the fifth leading cause of cancer death among women.
- Zacks•11 days ago
WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes
The WATCHMAN platform is expected to experience a strong quarter on consistent global momentum as Boston Scientific's (BSX) multiple market development efforts continue to push for growth.
- Market Realist•12 days ago
Abbott’s Latest Valuation Metrics in April 2018
On April 6, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings ratio) of 20.1x, while its PE was 57.6x. A lower forward estimate compared to the current PE represents analysts’ expectations that a company will generate higher earnings over the next 12 months.
- Market Realist•13 days ago
Abbott’s Stock Price Momentum Continues: What’s Ahead?
On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.
Markit•13 days agoSee what the IHS Markit Score report has to say about Boston Scientific Corp.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $15.80 billion.
Market Realist•13 days agoAnalysts’ Latest Recommendations and Target Prices for Abbott
Abbott Laboratories (ABT) showed an impressive performance in 2017 despite a challenging macroeconomic environment and big-ticket acquisitions. The company reported strong 2017 results on January 24, 2018, and it has secured a number of product approvals and reimbursement approvals since then, strengthening its market position.
- Market Realist•14 days ago
MitraClip Drives Growth, Gets Reimbursement Approval in Japan
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan. MitraClip is a minimally invasive procedure for patients suffering from MR (mitral regurgitation) who are at high risk of open surgery.
InvestorPlace•17 days ago5 Healthcare Stocks To Buy Today
From medical device firms to small biotech stocks, the healthcare sector has been hit hard over the last few weeks. With that, the recent patch of lower returns could be seen as huge buying opportunity for healthcare stocks for patient investors. There are all sorts of healthcare stocks that dabble in the medical devices sector, but none can compete with Boston Scientific Corporation (NYSE:BSX) in the heart disease sector.
- Market Realist•17 days ago
What’s behind Edwards Lifesciences’ Latest Valuation
Recent Developments at Edwards Lifesciences
Market Realist•17 days agoVarian Medical Systems: Expanding in Proton Therapy
Should Investors Be Interested in Varian Medical Systems?
Market Realist•18 days agoEdwards Lifesciences Gets CE Mark Approval for Its Centera Valve
Recent Developments at Edwards Lifesciences
- ACCESSWIRE•18 days ago
Today’s Research Reports on Stocks to Watch: Loxo Oncology and Boston Scientific
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Shares of Loxo Oncology were gaining heavily in Wednesday trading after the company announced that it would be presenting interim results of its Phase 1 clinical ...
- Market Realist•18 days ago
Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?
Should Investors Be Interested in Varian Medical Systems? Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution. Since the launch of this radiotherapy solution in 4Q16, the company has secured 57 orders, of which 19 were placed in 1Q18.
- Market Realist•19 days ago
What’s Driving Boston Scientific Stock Upward
Boston Scientific Acquires Securus Medical
- Market Realist•19 days ago
Wall Street’s Recommendations for BSX Stock
Boston Scientific Acquires Securus Medical
Market Realist•19 days agoBoston Scientific Announces Acquisition of Securus Medical
Boston Scientific Acquires Securus MedicalBoston Scientific’s Securus Medical acquisition
- Market Realist•19 days ago
Edwards Lifesciences and Boston Scientific: Patent Dispute Update
On March 23, 2018, Edwards Lifesciences (EW) announced that it won its dispute with Boston Scientific (BSX) over US Patent 8992608. The USPTO (US Patent and Trademark Office) decided in favor of Edwards in an inter partes review filed by Boston Scientific against Edwards for its TAVR (transcatheter aortic valve replacement) technology, finding all the related claims against Edwards to be invalid.
- Zacks•19 days ago
Boston Scientific to Acquire Securus Medical, Boost EP Unit
Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.
